Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Long Qt Syndrome 5 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Long Qt Syndrome 5 with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Corneal Dystrophy, Lisch Epithelial Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Corneal Dystrophy, Lisch in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Dental Enamel Hypoplasia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Dental Enamel Hypoplasia in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hypopigmentation Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Hypopigmentation with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Dysosteosclerosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Dysosteosclerosis with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Thrombocytopenia, Neonatal Alloimmune Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Thrombocytopenia, Neonatal in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Nephrosis, Congenital Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Nephrosis, Congenital with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Long Qt Syndrome 3 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Long Qt Syndrome 3 with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Disorders of Sex Development Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Disorders of Sex Development in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Idiopathic Membranous Glomerulonephritis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Idiopathic Membranous in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Metabolic Diseases Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Metabolic Diseases with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Papillary Adenocarcinoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Papillary Adenocarcinoma in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..